Spots Global Cancer Trial Database for topotecan
Every month we try and update this database with for topotecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan | NCT02030964 | Neuroblastoma | DFMO Celecoxib Cyclophosphamid... Topotecan | 2 Years - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | NCT00732420 | Solid Tumours | topotecan pazopanib | 18 Years - | GlaxoSmithKline | |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT06161025 | Solid Cancer | R-DXd Gemcitabine Paclitaxel Topotecan PLD | 18 Years - | Daiichi Sankyo | |
| A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | NCT00259935 | Lung Cancer, Sm... | topotecan | 18 Years - | GlaxoSmithKline | |
| Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma | NCT00901238 | Retinoblastoma | Intra-arterial ... | 1 Month - | Weill Medical College of Cornell University | |
| Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | NCT04768296 | Small-cell Lung... | Berzosertib Berzosertib Topotecan | 18 Years - | EMD Serono | |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | NCT02298348 | Neuroblastoma | Sorafenib Cyclophosphamid... Topotecan | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | NCT00657878 | Ovarian Cancer | stealth liposom... carboplatin paclitaxel Topotecan Gemcitabine | - | National Cancer Institute, Naples | |
| Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | NCT00113789 | Ovarian Cancer | PI Discretion | 18 Years - | Amgen | |
| Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | NCT00325416 | Multiple Myelom... | melphalan topotecan (TPT) Autologous Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | NCT00001335 | Ewing's Sarcoma Neuroblastoma Rhabdomyosarcom... | ADR-529 Topotecan G-CSF | - | National Institutes of Health Clinical Center (CC) | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors | NCT01342237 | Brain Tumors | HDCT 1(TTC), HD... | - | Seoul National University Hospital | |
| Meta-analysis of Efficacy of Topotecan | NCT01160185 | Cervical Intrae... | paclitaxel cisplatin topotecan | 21 Years - | GlaxoSmithKline | |
| Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | NCT03088813 | Small Cell Lung... | Irinotecan lipo... Topotecan | 18 Years - | Ipsen | |
| Regulatory Hycamtin(Oral) PMS | NCT01037023 | Lung Cancer, Sm... | Topotecan | - | GlaxoSmithKline | |
| Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | NCT00477282 | Ovarian Cancer | Karenitecin Topotecan | 18 Years - | BioNumerik Pharmaceuticals, Inc. | |
| Topotecan and Melphalan for Retinoblastoma | NCT04799002 | Retinoblastoma Chemotherapy Ef... | Topotecan Melphalan | - | Sun Yat-sen University | |
| Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma | NCT00901238 | Retinoblastoma | Intra-arterial ... | 1 Month - | Weill Medical College of Cornell University | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors | NCT00502892 | Solid Tumors | Topotecan Ifosfamide Carboplatin | - 45 Years | M.D. Anderson Cancer Center | |
| Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | NCT05874401 | Extensive-stage... | Trilaciclib Placebo Topotecan | 18 Years - | G1 Therapeutics, Inc. | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | NCT02390843 | Retinoblastoma Clear Cell Sarc... Renal Cell Carc... Rhabdoid Tumor Wilms Tumor Hepatoblastoma Neuroblastoma Germ Cell Tumor... Ewings Sarcoma Non-rhabdomyosa... Osteosarcoma Rhabdomyosarcom... | Simvastatin Cyclophosphamid... Topotecan Myeloid growth ... | 1 Year - 29 Years | Emory University | |
| BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | NCT01121406 | Ovarian Neoplas... | Paclitaxel Gemcitabine Topotecan Pegylated lipos... BI 6727 | 18 Years - | Boehringer Ingelheim | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan | NCT05990738 | Small Cell Lung... | BI 764532 Topotecan | 18 Years - | Boehringer Ingelheim | |
| A Study of N9 Chemotherapy in Children With Neuroblastoma | NCT04947501 | Neuroblastoma Pediatric Cance... | Cyclophosphamid... Topotecan Vincristine Doxorubicin Ifosfamide Etoposide Carboplatin Mesna | 1 Year - 19 Years | Memorial Sloan Kettering Cancer Center | |
| Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer | NCT00320983 | Cervical Cancer | Topotecan Cisplatin | - | University of New Mexico | |
| Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | NCT00113789 | Ovarian Cancer | PI Discretion | 18 Years - | Amgen | |
| A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | NCT00046111 | Lung Cancer, Sm... Solid Tumor Can... | topotecan | 18 Years - | GlaxoSmithKline | |
| Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors | NCT00193583 | Cancer | Topotecan Carboplatin | 18 Years - | SCRI Development Innovations, LLC | |
| Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors | NCT00193570 | Cancer | Topotecan Docetaxel | 18 Years - | SCRI Development Innovations, LLC | |
| Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | NCT01783535 | Retinoblastoma | vincristine topotecan filgrastim PEG-filgrastim carboplatin focal therapy etoposide cyclophosphamid... MESNA doxorubicin enucleation external beam r... | - | St. Jude Children's Research Hospital | |
| A Study of N9 Chemotherapy in Children With Neuroblastoma | NCT04947501 | Neuroblastoma Pediatric Cance... | Cyclophosphamid... Topotecan Vincristine Doxorubicin Ifosfamide Etoposide Carboplatin Mesna | 1 Year - 19 Years | Memorial Sloan Kettering Cancer Center | |
| Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | NCT00319969 | Small Cell Lung... | Amrubicin Topotecan | 18 Years - | Celgene | |
| A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | NCT00259935 | Lung Cancer, Sm... | topotecan | 18 Years - | GlaxoSmithKline | |
| Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer | NCT02481830 | Lung Cancer | Nivolumab Topotecan Amrubicin | 18 Years - | Bristol-Myers Squibb | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | NCT04029688 | Acute Myeloid L... Acute Lymphobla... Neuroblastoma Solid Tumors | Idasanutlin Venetoclax Cyclophosphamid... Topotecan Fludarabine Cytarabine Intrathecal Che... | 0 Years - 30 Years | Hoffmann-La Roche | |
| Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer | NCT00102375 | Ovarian Cancer | Topotecan | 18 Years - | AGO Study Group | |
| Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | NCT00325416 | Multiple Myelom... | melphalan topotecan (TPT) Autologous Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Topotecan Pharmacokinetic Characterization Study | NCT00361803 | Cancer | topotecan | 18 Years - | GlaxoSmithKline | |
| Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | NCT03600649 | Ewing Sarcoma Myxoid Liposarc... Sarcoma,Soft Ti... Desmoplastic Sm... Extraskeletal M... Angiomatoid Fib... Clear Cell Sarc... Primary Pulmona... Myoepithelial T... Sclerosing Epit... Fibromyxoid Tum... | Seclidemstat Cyclophosphamid... Topotecan | 12 Years - | Salarius Pharmaceuticals, LLC | |
| Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | NCT00601003 | Neuroblastoma Medulloblastoma | Nifurtimox Cyclophosphamid... Topotecan | - 21 Years | Milton S. Hershey Medical Center | |
| Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | NCT00397293 | Small Cell Lung... | AT-101 topotecan | 18 Years - | Ascenta Therapeutics | |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | NCT02566993 | Small-cell Lung... | Lurbinectedin (... Doxorubicin (DO... Cyclophosphamid... Vincristine (VC... Topotecan | 18 Years - | PharmaMar | |
| A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | NCT01840943 | Epithelial Ovar... | CAELYX Topotecan HCl | 18 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer | NCT01417806 | Small Cell Lung... | Topotecan and P... | 18 Years - | South Florida Veterans Affairs Foundation for Research and Education | |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | NCT02566993 | Small-cell Lung... | Lurbinectedin (... Doxorubicin (DO... Cyclophosphamid... Vincristine (VC... Topotecan | 18 Years - | PharmaMar | |
| Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer | NCT00193401 | Lung Cancer | Topotecan | 18 Years - | SCRI Development Innovations, LLC | |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | NCT03786783 | Ganglioneurobla... High Risk Neuro... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Dexrazoxane Dinutuximab Doxorubicin Etoposide External Beam R... Isotretinoin Melphalan Sargramostim Thiotepa Topotecan Vincristine | - 30 Years | National Cancer Institute (NCI) | |
| Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | NCT02980809 | Small Cell Lung... | Apatinib Topotecan | 18 Years - | First Hospitals affiliated to the China PLA General Hospital | |
| Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | NCT00744081 | AML | Glivec Mitoxantrone Topotecan AraC | 18 Years - | Goethe University | |
| Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer | NCT00888810 | Cancer Ovarian Relapse Chemotherapy | TOPOTECAN LAPATINIB | 18 Years - | Centre Francois Baclesse | |
| Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | NCT02421588 | Ovarian Cancer | Lurbinectedin (... Pegylated lipos... Topotecan | 18 Years - | PharmaMar | |
| A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | NCT01497873 | Small Cell Lung... | Topotecan Belotecan | 18 Years - | Chong Kun Dang Pharmaceutical | |
| Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | NCT00189566 | Ovarian Cancer Fallopian Tube ... Malignant Tumor... | Paclitaxel Topotecan Carboplatin | 18 Years - | ARCAGY/ GINECO GROUP | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) | NCT01076400 | Cervical Cancer | adavosertib Topotecan Cisplatin Placebo to adav... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | NCT05740566 | Small Cell Lung... | Tarlatamab Lurbinectedin Topotecan Amrubicin | 18 Years - | Amgen | |
| Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer | NCT00322751 | Lung Cancer | Topotecan | 18 Years - | University of New Mexico | |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers | NCT00703807 | Endometrial Can... | Topotecan RAD001 | 18 Years - | Yale University | |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | NCT00315861 | Ovarian Cancer Endometrial Can... Cervical Cancer Lung Cancer | pemetrexed topotecan | 18 Years - | SCRI Development Innovations, LLC | |
| Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | NCT00526799 | Ovarian Cancer | Sorafenib Topotecan | 18 Years - | Hoosier Cancer Research Network | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | NCT04073550 | Small Cell Lung... | Anlotinib Placebos Topotecan | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer | NCT00193401 | Lung Cancer | Topotecan | 18 Years - | SCRI Development Innovations, LLC | |
| Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer | NCT00049998 | Non-Small-Cell ... | topotecan | 18 Years - | GlaxoSmithKline | |
| Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | NCT02903004 | Ovarian Neoplas... | Trabectedin Pegylated Lipos... Topotecan Gemcitabine Weekly Paclitax... Carboplatin | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | NCT05800587 | Lung Cancer Small-cell Lung... Non Small Cell ... | Carboplatin Pemetrexed Paclitaxel Nab paclitaxel Docetaxel Gemcitabine Etoposide Irinotecan Topotecan Lurbinectedin | 18 Years - | Fox Chase Cancer Center | |
| Study in Patients With SCLC of Veliparib in Combination With Topotecan | NCT03227016 | Small Cell Lung... | veliparib Topotecan | 18 Years - 85 Years | Central European Society for Anticancer Drug Research | |
| Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer | NCT00305942 | Carcinoma, Smal... | Topotecan carboplatin | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | NCT02200757 | Metastatic Smal... | Aldoxorubicin Topotecan | 18 Years - | CytRx | |
| AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy | NCT00547651 | Small Cell Lung... | Amrubicin Topotecan | 18 Years - | Celgene | |
| a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4 | NCT00130858 | Sarcoma, Soft T... | Topotecan Carboplatin | - 21 Years | Cooperative Weichteilsarkom Study Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
